Scarless Circular mRNA In Vivo CAR-T Exhibits Potent Pharmacological Efficacy in Preclinical Models
- CellectLNP is a versatile platform for modular engineering of antibody-conjugated LNPs to achieve efficient and selective in vivo CAR cmRNA delivery to T cells
- cmCAR, a prolonged and enhanced CAR expression platform enabled by scarless circular mRNA technology, exhibits superior efficiency for in vivo engineering of CAR-T cells
- Robust anti-cancer activity and profound B cell-depletion in humanized mouse models and non-human primates by in vivo circular mRNA CAR, providing novel opportunities for cancers and autoimmune diseases